E. Van-cutsem, C. Köhne, I. Láng, G. Folprecht, M. Nowacki et al., Mutation Status, Journal of Clinical Oncology, vol.29, issue.15, pp.292011-2019, 2011.
DOI : 10.1200/JCO.2010.33.5091

A. Lièvre, J. Bachet, V. Boige, A. Cayre, L. Corre et al., Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.26, issue.3, pp.374-379, 2008.
DOI : 10.1200/JCO.2007.12.5906

M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi et al., Gefitinib or Chemotherapy for Non???Small-Cell Lung Cancer with Mutated EGFR, New England Journal of Medicine, vol.362, issue.25, pp.3622380-2388, 2010.
DOI : 10.1056/NEJMoa0909530

P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, issue.26, pp.3642507-2516, 2011.

E. Romond, E. Perez, J. Bryant, V. Suman, C. Geyer et al., Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.3531673-84, 2005.
DOI : 10.1056/NEJMoa052122

E. Perez, V. Suman, N. Davidson, S. Martino, P. Kaufman et al., Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial, Journal of Clinical Oncology, vol.24, issue.19, pp.243032-243040, 2006.
DOI : 10.1200/JCO.2005.03.4744

C. Tse, H. Hwang, L. Goldstein, P. Kandalaft, J. Wiley et al., Targeted Therapy, Journal of Clinical Oncology, vol.29, issue.31, pp.294168-74, 2011.
DOI : 10.1200/JCO.2011.36.0107

J. Sosman, K. Kim, L. Schuchter, R. Gonzalez, A. Pavlick et al., Survival in BRAF V600???Mutant Advanced Melanoma Treated with Vemurafenib, New England Journal of Medicine, vol.366, issue.8, pp.366707-366721
DOI : 10.1056/NEJMoa1112302

A. Hauschild, J. Grob, L. Demidov, T. Jouary, R. Gutzmer et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, vol.380, issue.9839, pp.380358-65
DOI : 10.1016/S0140-6736(12)60868-X

K. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe et al., Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma, New England Journal of Medicine, vol.367, issue.2, pp.107-121
DOI : 10.1056/NEJMoa1203421

F. Nowak, J. Soria, and F. Calvo, Tumour molecular profiling for deciding therapy???the French initiative, Nature Reviews Clinical Oncology, vol.456, issue.8, pp.479-86
DOI : 10.1038/nrclinonc.2012.42

S. Moreau, P. Saiag, P. Aegerter, D. Bosset, C. Longvert et al., Prognostic value of BRAF(V 600 ) mutations in melanoma patients after resection of metastatic lymph nodes, Ann Surg Oncol, vol.2012, issue.13, pp.194314-194335

E. Colomba, Z. Hélias-rodzewicz, V. Deimling, A. Marin, C. Terrones et al., Detection of BRAF p.V600E Mutations in Melanomas, The Journal of Molecular Diagnostics, vol.15, issue.1, pp.94-100
DOI : 10.1016/j.jmoldx.2012.09.001

A. Didelot, L. Corre, D. Luscan, A. Cazes, A. Pallier et al., Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples, Experimental and Molecular Pathology, vol.92, issue.3, pp.92275-80
DOI : 10.1016/j.yexmp.2012.03.001

H. Blons, E. Rouleau, N. Charrier, G. Chatellier, J. Côté et al., Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience, PLoS ONE, vol.12, issue.7, p.68945, 2013.
DOI : 10.1371/journal.pone.0068945.s002

URL : https://hal.archives-ouvertes.fr/hal-00974911

S. Anderson, K. Bloom, D. Vallera, J. Rueschoff, C. Meldrum et al., Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalinfixed , paraffin-embedded tissue specimens of malignant melanoma, Arch Pathol Lab Med, vol.2012, issue.11, pp.1361385-91

H. Do, S. Wong, J. Li, and A. Dobrovic, Reducing Sequence Artifacts in Amplicon-Based Massively Parallel Sequencing of Formalin-Fixed Paraffin-Embedded DNA by Enzymatic Depletion of Uracil-Containing Templates, Clinical Chemistry, vol.59, issue.9, pp.1376-83, 2013.
DOI : 10.1373/clinchem.2012.202390